TickerGuard
Buy Day today: Neutral (58) Mixed market breadth · no major macro event
IKT

Inhibikase Therapeutics Inc

Healthcare · Biotechnology

2.00$ +0.0% vs. previous close Closing price · As of: Oct 5, 2026

Statements

Balance Sheet

Inhibikase Therapeutics Inc (IKT) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Total Assets" came in at 164 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Balance Sheet IKT
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26
18 15 11 8.8 4.4 99 94 89 80 181 173 164
18 14 11 8.6 4.2 98 94 89 79 180 172 162
15 9.2 2.4 3.1 0.9 56 73 78 38 139 50 31
17 13 9.7 7.9 3.2 98 93 88 77 179 170 159
0.0 0.0 0.0 – – – – – – – – –
1.1 – – – – – – – – – – –
2.9 3.5 4.3 3.7 4.9 3.7 8.6 8.8 6.7 8.3 5.7 10
2.7 3.4 4.2 3.7 4.9 3.7 8.6 8.8 6.7 8.3 5.7 10
0.1 0.5 0.4 0.3 0.2 0.1 0.1 0.0 – – – –
0.7 0.6 1.3 1.3 2.5 0.9 1.7 2.7 0.6 1.2 1.6 1.0
15 11 6.8 5.1 -0.5 95 86 80 73 173 168 153
-63 -67 -72 -77 -82 -94 -108 -118 -130 -143 -159 -179
5.3 6.2 6.3 7.5 8.9 16 90 90 90 94 172 175

Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?